B lymphoma cells are more sensitive to macrophages in the presence of rituximab.164 Its combination with cyclophosphamide induced nearly complete tumor elimination in resistant bone marrow by activating macrophages.165 After blocking the CD47-SIRPα axis, rituximab-induced macrophage phagocytosis was augmented in nongerminal center B diffuse large B-cell lymphoma patients.166 Trastuzumab is an HER2-targeting antibody that has shown promising efficacy in breast cancer therapy. This evidence concerns the gene SIRPA and neoplasm.